Expands DehydraTECH™ B2B manufacturing capabilities to support Lexaria's growing corporate customer base
Lexaria to also receive royalty revenue from DehydraTECH product sales through BevNology's commercial license rights
KELOWNA, BC / ACCESSWIRE / June 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the signing of two agreements with Atlanta-based BevNology LLC ("BevNology").
The first agreement is a manufacturing operating agreement that expands production capabilities for Lexaria's own growing list of business-to-business ("B2B") clientele interested in purchasing DehydraTECH-powered active ingredients for consumer packaged-goods brands. A new, state-of-the-art processing facility custom-built by BevNology is operational that increases and broadens production capacity and is currently serving Lexaria's corporate clients. Lexaria has moved and installed all required commercial DehydraTECH manufacturing equipment into BevNology's new facility as it prepares for future growth in its B2B ingredient processing business.
The second agreement is a commercial license agreement that empowers BevNology to offer DehydraTECH products with active ingredients derived from hemp including cannabidiol ("CBD") under BevNology and partnered brands. For powdered DehydraTECH formulations this agreement is non-exclusive. For liquid DehydraTECH formulations, where BevNology has highly specialized skills and capabilities, the license is non-exclusive in most areas of the world but includes limited exclusivity rights in the United States only, that require certain minimum fee payments in order to maintain those rights. Lexaria will receive royalties from BevNology as a result of their utilization of this license. The only countries specifically excluded under this license are Japan, the Republic of Korea, and the People's Republic of China.
"We are very excited about this expanded partnership with Lexaria, which will further strengthen our longtime relationship as well as boost our development and manufacturing capabilities through the addition of our new facility. This will allow us to expand our product and service offerings," said Gonzalo de Aristegui, partner and co-founder of Bevnology.
Founded 10 years ago by Louis Heinsz and Gonzalo de Aristegui, Bevnology is the product development and manufacturing arm of IBC (InterContinental Beverage Capital). It operates a state of the art lab and manufacturing facility outside Atlanta, Georgia
"These agreements build on a long standing and very successful product development consulting relationship between Lexaria and the expert scientists and personnel at BevNology," said Chris Bunka, CEO of Lexaria. "BevNology's formulation and production capabilities are class leading and we are confident that our new relationship with our trusted partner will propel new and exciting growth opportunities for both companies."
Bevnology has advanced capabilities that support best-in-class beverage formulations and, together with Lexaria's superior technology, could make industry-leading beverage products a reality for many brands. Lexaria's DehydraTECHTM-CBD nanoemulsification formulation and processing techniques exhibited exceptional stability one year after production with less than 1% variability in CBD potency in fractions sampled from the top, middle and bottom of the beverage formulation without physical mixing or agitation; and, CBD content was verified at 93.4% of target potency and also evidenced excellent microbial purity after 12 months.
The latest stability testing occurred 25 months after originally bottling, with slightly higher variability but still retaining an average 78% of originally formulated CBD. As well, the microbiologic purity and cleanliness of the product exceeded all requirements 25 months after bottling.
Lexaria's DehydraTECH technology has been embraced by several consumer-packaged goods brands currently available in over 7,000 stores in the US and Japan, as well as through direct-to-consumer online retail portals.
BevNology is a leading beverage development and advisory company with the focus on providing top-notch formulation and commercialization services of cutting-edge beverage products for both new and existing brands. BevNology's outside the box thinking as well as creative product development innovation has earned them the top position in the beverage industry. The team at BevNology each have over 30 years of beverage development and beverage design experience in the Beverage Industry.
Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, please visit www.lexariabioscience.com.
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
George Jurcic - Head of Investor Relations ir@lexariabioscience.com Phone: 250-765-6424, ext 202
View source version on accesswire.com: https://www.accesswire.com/705874/Lexaria-Signs-Manufacturing-and-License-Agreements-with-BevNology
Does the June share price for CloudMD Software & Services Inc. ( CVE:DOC ) reflect what it's really worth? Today, we...
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Data Storage...
The Germantown med-tech firm makes an implantable continuous glucose monitoring system for diabetes patients.
Calit Advisors Partner Lenore Elle Hawkins joins Yahoo Finance Live to discuss the state of the economy, stock futures, consumer sentiment report data, May retail sales, retail inventories, inflation, and the outlook for a recession.
Since hitting their respective all-time closing highs, the 126-year-old Dow Jones Industrial Average, benchmark S&P 500, and growth-focused Nasdaq Composite have respectively fallen by as much as 19%, 24%, and 34%. This means the Nasdaq and S&P 500 are officially in the grip of a bear market. To make matters worse, there's the growing likelihood that the U.S. could enter a recession.
In this article we present the list of Louis Navellier is Buying These 10 Energy Stocks in 2022. Click to skip ahead and see the Louis Navellier is Buying These 5 Energy Stocks in 2022. ConocoPhillips (NYSE:COP), Phillips 66 (NYSE:PSX), and Devon Energy Corporation (NYSE:DVN) represent some of the biggest purchases of energy stocks made by […]
Wall Street is nervous a recession is right around the corner. But analysts think some S&P 500 companies have sunk into one already.
The founder of ARK Invest, Wall Street's best-known tech sector evangelist, warns leading economic indicators are flashing red.
With its stock down 27% over the past three months, it is easy to disregard Himax Technologies (NASDAQ:HIMX). But if...
Last week, the Fed’s open market committee raised its benchmark interest rate by 0.75%, the largest such increase in almost 30 years. The move marks a shift to an aggressive stance against inflation, and an attempt by the Fed to head off a potential recession. In fact, preliminary data leaked from the Atlanta Fed earlier in the week showed that the US is in a technical recession. While official numbers won’t be released until after the second quarter ends, the early numbers show that 2Q22 will e
Just a few months ago real estate was flying high. But with mortgage rates rising, brokers are already seeing a sharp slowdown in buyers. The big builders are better positioned to weather a recession.
The CEO told a conference in Qatar that the electric-vehicle company can sell as many cars as it can produce and that the waiting list is long.
The stock market is in bad shape this year. The stock market gloom means that some big names that have performed well in the past have also crashed substantially. Taiwan Semiconductor Manufacturing (NYSE: TSM), popularly known as TSMC, and Meta Platforms (NASDAQ: META) are down 29.4% and 51.3%, respectively, so far in 2022.
Jefferies Equity Research Analyst Brent Thill joins Yahoo Finance Live to discuss market volatility, tech stocks, and the outlook for investors.
Yahoo Finance Live anchors discuss the Tesla’s plans to proceed with layoffs.
Kellogg Co. shares jumped 8.1% in Tuesday premarket trading after the food company announced a plan to split into three businesses: "Global Snacking Co.," which will represent about $11.4 billion in sales and include international cereal and noodles, North American frozen breakfast, as well as snacks; "North America Cereal Co.," which represents about $2.4 billion in sales and includes U.S., Canada, and Caribbean cereals; and "Plant Co.," a business of about $340 million anchored by the MorningS
The Microstrategy CEO, who turned his software company into a bet on Bitcoin, believes competing digital tokens and many crypto stakeholders like exchanges scare off professional investors due to "all the slime that gets onto the asset class" from their unregulated behavior.
Here's what a fundamental and technical analysis says about Google stock. GOOGL stock buybacks remain high as web search and YouTube advertising rebound. But cloud computing growth is key.
Investing in equal parts of Raytheon Technologies (NYSE: RTX), 3M (NYSE: MMM), and Clearway Energy (NYSE: CWEN) gives you an average dividend yield of 3.8% and exposure to the defense industry, the industrial sector, consumer products, healthcare, automation and robotics, and renewable energy. Lee Samaha (Raytheon Technologies): This aerospace and defense giant is a rare beast -- one of the few companies whose stock is up in 2022.
You probably don't need me to tell you this, but this has been one of the most challenging years on record for Wall Street and investors. In the roughly five to seven months since all three major U.S. indexes hit their all-time closing highs, the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite have respectively plunged as much as 19%, 24%, and 34%. Heightened stock market volatility has been particularly cruel to technology-based growth stocks, which had been largely responsible for the monstrous rally that followed the March 2020 pandemic bottom.